Mineralys Therapeutics (Nasdaq: MLYS) has reported positive top-line results from two pivotal trials evaluating lorundrostat, a potentially new option for uncontrolled and resistant hypertension.
The company said both studies, Launch-HTN and Advance-HTN, met their primary endpoints with statistically-significant reductions in blood pressure.
The Phase III Launch-HTN study demonstrated a 9.1 mmHg placebo-adjusted reduction in systolic blood pressure at six weeks, while the Advance-HTN trial saw a 7.9 mmHg reduction at 12 weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze